To investigate the effect of SR141716, a selective CB1 receptor antagonist, on energy expenditure and on glucose uptake in isolated soleus muscle of Lep ob /Lep ob mice. DESIGN: Female Lep ob /Lep ob mice (8-10 weeks old) were treated with SR141716 (10 mg/kg, i.p. once daily) or vehicle for 7 days. MEASUREMENTS: Oxygen consumption, daily food and water intake, body weight and glucose uptake in isolated soleus muscle. RESULTS: SR141716 (10 mg/kg, i.p. once daily) resulted in a significant reduction of daily food intake (Po0.01) and body weight (Po0.05) 5 days after daily treatment. Body weight continued to be lower for the rest of the treatment period (Po0.05). There was no significant difference in body weight between the pair-fed and vehicle-treated animals. A 7-day treatment with SR141716 (10 mg/kg, i.p. once daily) caused 37% increase in basal oxygen consumption compared to that of vehicle-treated (90 min mean; Po0.01), and a significant 68% increase in glucose uptake in isolated soleus muscle preparations. CONCLUSION: It is concluded that SR141716 has a direct effect on energy expenditure suggesting that the antiobesity effect of SR141716 is due to activation of thermogenesis in addition to the initial hypophagia. The increase in soleus muscle glucose uptake with SR141716 treatment may contribute to the improved glycaemia seen in the previous studies.
Introduction
Hypothalamic endocannabinoids are negatively controlled by leptin and are considered to belong to the growing family of orexigenic mediators, such as neuropeptideY (NPY), Agouti-related protein (Agrp), melanin concentrating hormone (MCH) and the orexins. [1] [2] [3] [4] [5] The hypothalamic level of endocannabinoids is increased in genetically obese animals, 1 which suggests that it may contribute to the hyperphagia that leads to obesity in those animals. Furthermore, it has been shown that the endocannabinoids, anandamide and 2-arachidonoyl glycerol stimulate feeding via activation of the cannabinoid CB1 receptors. 6, 7 SR141716 is a potent and selective central cannabinoid receptor antagonist 8 and it antagonises the hyperphagia induced by anandamide and 2-arachidonoyl glycerol. 7, 9 In addition to its effect on food intake, SR141716 dosedependently decreased body weight gain in obese Zucker (fa/fa) rats and this effect was greater in obese Zuckers than their lean littermates. 10 In another study, daily treatment with SR141716 in obese Zucker rats reduced body weight by 20% after 4 days and throughout the 2-week treatment period, whereas food intake became comparable with that of lean rats. 11 Further indication that SR141716 may affect energy expenditure in addition to food intake came from a study in dietary obese mice where chronic treatment with SR141716 caused sustained reduction of body weight and adiposity with only a transient reduction of food intake. 
Measurement of food intake and body weight
Three groups of mice housed in pairs were acclimatised to the experimental condition (eg being handled) 1 week before the experiments were conducted. Food consumption and body weight were recorded daily between 1000 and 1100 hours prior to drug administration. Vehicle (2 ml/kg) or SR141716 (10 mg/kg; i.p.) was administered once daily at 1100 hours for a period of 7 days. For the pair-fed, the amount of food given each day was the mean daily food consumption of the SR141716-treated mice.
Measurement of oxygen consumption
Oxygen consumption (VO 2 ) was determined in closed-circuit respirometers maintained at the thermoneutral temperature (291C). As the system was originally designed for testing an individual rat per chamber, 13 a trial experiment with mice was carried out to test the sensitivity of the system using a potent thermogenic agent, sibutramine metabolite 2, 14, 15 where a significant rise in oxygen consumption after a single dose was achieved by placing two mice per chamber (data not shown). Therefore, it was decided to use two mice per testing chamber and the mean VO 2 was taken. All animals were accustomed to the respirometers and procedures on three occasions the week before the experiments. Oxygen consumption was recorded on a computer every 5 min and expressed as millilitre of oxygen per kilogram of metabolic body size per minute (ie ml/kg 0.75 /min). For the acute experiment (first injection), after a 120-min baseline measurement (the mean of the last 30 min of the baseline readings was taken as the value for time 0), mice were taken out of the chamber and given an i.p. injection of either vehicle (2 ml/kg) or SR141716 at a dose of 10 mg/kg at 1100 hours. They were then returned to the chambers and measurement of VO 2 continued for a further 180 min. The 30 min averages of VO 2 were used to plot the time course of the acute responses. At the end of the testing period, animals were returned to their home cages and treated with either SR141716 (10 mg/kg, i.p.) or vehicle once daily at 1100 hours for another 6 days. At 22 h after the last day injection, mice were put into the chamber again at 900 hours and baseline VO 2 was measured for 90 min.
Measurement of 2-deoxyglucose uptake and phosphorylation in isolated soleus muscle Rate of uptake and phosphorylation of 2-deoxyglucose was measured as previously described. 16 At the end of basal VO 2 measurement after a 7-day treatment period (23.5 h after the last injection), mice were killed by cerebral dislocation. Both proximal and distal tendons of the soleus muscle were ligated, and the muscle was then removed and secured to a stainless steel clip under slight tension designed to approximate that of the resting muscle. 17 They were immediately placed in 3 ml of Krebs Henseleit Bicarbonate (KHB) medium (previously gassed with 95% O 2 :5% CO 2 ) containing 0.14% fatty acid-free bovine serum albumin and 5.5 mM glucose and preincubated for 30 min at 371C in a shaking water bath (120 strokes/min) with continuous 95% O 2 :5% CO 2 gassing. At the end of the preincubation period, muscle plus clip were quickly rinsed in KHB and transferred to a new flask containing 3 ml of the same KHB-bovine serum albumin medium, with 10 nM insulin (to maintain tissue viability) and 2-deoxy-[ 3 H]-glucose (1 mCi/ml), and incubated for a further 60 min with continuous gassing. At the end of the 60 min, muscles were removed and quickly frozen in liquid N 2 . Tissues were then digested in 0.5 ml of 1 M NaOH at 601C for 45 min and neutralised with 0.5 ml of 1 M HCl. A 200 ml aliquot was added to 1 ml of 6% HClO 4 
Results
Effect of SR141716 on daily food intake and body weight SR141716 (10 mg/kg, i. p. once daily) had no significant effect on daily food intake during the first 4 days post treatment. A significant, 25% reduction in daily food intake was seen 5 days after the daily treatment with SR141716 as compared to that of vehicle-treated group (Po0.01; Figure 1a ). The decrease in food consumption in the SR141716-treated group was sustained on day 6 post treatment (20% reduction, Po0.05, Figure 1a ). There was no significant difference in body weight between controland SR141716-treated groups prior to the first injection (control: 40.270.5 g; SR141716: 40.070.6 g). SR141716 (10 mg/kg, i.p.) resulted in a small, but significant decrease in body weight 5 days after the daily treatment and for the rest of the treatment period as compared to that of vehicletreated animals (Po0.05, Figure 1b ). There was no significant difference in body weight change between the pair-fed and vehicle-treated animals during the 7-day treatment period (Figure 1b) .
Effect of SR141716 on oxygen consumption
The potential thermogenic property of SR141716 was determined by measuring oxygen consumption (VO 2 ). The time course of the VO 2 response (over 180 min) to a single dose of SR141716 (10 mg/kg, i.p.; first injection) was shown in Figure 2a . SR141716 caused a 49% increase in VO 2 30 min post administration although this did not reach significance (Figure 2a) . VO 2 was measured again after a 7-day treatment with either SR141716 (10 mg/kg, once daily) or vehicle. Basal VO 2 was measured (22 h after the last dose) for 90 min in both vehicle-and SR141716-treated animals. The mean VO 2 for the 90 min period was significantly higher in SR141716-treated group compared to the vehicle-treated (7.170.3 ml/ kg 0.75 /min for SR141716; 5.270.4 ml/kg 0.75 /min for vehicle;
Po0.01, Figure 2b ).
Effect of SR141716 on glucose uptake in isolated soleus muscle 2-Deoxyglucose is transported and phosphorylated in a similar manner to glucose, but is not metabolised further. Figure 3 shows the rate of glucose uptake (formation of 2-deoxyglucose-6-phosphate) by soleus muscle after a 7-day treatment with either SR141716 (10 mg/kg once daily) or vehicle. Treatment with SR141716 resulted in a significant Figure 3 ).
Discussion
The present study demonstrates the ability of the CB1 receptor antagonist SR141716 to cause reduction in food consumption and body weight in Lep ob /Lep ob mice, a model of genetic obesity and NIDDM. Significant reduction of food intake was seen on day 5 and 6 post SR141716 treatment. This hypophagic effect of SR141716 is consistent with previous studies, 1,10-12 although the onset of the effect was slower. It has been shown that SR141716 can inhibit food intake in food-restricted NPY-deficient mice, suggesting that endocannabinoids may compensate for the lack of NPY in maintaining food intake. 1 Crosstalk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) has been reported recently and that CB1 receptor is able to potentiate the orexin receptor 1, 20 which suggests that SR141716 may be a potent modulator of the orexin A system. Thus, the endocannabinoids is now considered to belong to the growing family of orexigenic mediators such as NPY, Agrp, MCH and the orexins. SR141716 (10 mg/kg, i.p.) resulted in a small but significant decrease in body weight 5 days after the daily treatment, which was sustained for the rest of the treatment period (7 days). This decrease in body weight induced by SR141716 in Lep ob /Lep ob mice is less marked than that in dietinduced obese mice where treatment with SR141716 produced a 13% decrease at day 3 and a 20% decrease at the end of a 5-week treatment compared to the controls. This difference in the response to SR141716 between those two animal models could be due (at least partly) to the lack of leptin in the Lep ob /Lep ob mice, although reduced central leptin sensitivity has been found in diet-induced obese rats 21 but only peripheral leptin resistance has been reported in diet-induced obese mice. 22 The fact that there was no significant difference in body weight between the pair-fed and the vehicle-treated mice in the present study suggests that the decrease in food intake is not solely responsible for the decrease in body weight seen with SR141716 treatment. Thus, it was decided to investigate the potential thermogenic role of SR141716 in these animals. Our data provided the first direct evidence that chronic treatment with SR141716 activates thermogenesis as indicated by a significant 37% increase in basal oxygen consumption after 7-day treatment in Lep ob /Lep ob mice. This may explain the sustained effect of SR141716 on body weight with only transient hypophagia seen in previous studies. 11 The ability of SR141716 to reduce body weight is therefore due to the increase in energy expenditure. In the present study, a single dose of SR141716 (10 mg/kg, i.p.) resulted in a 49% increase in oxygen consumption at 30 min post administration although this did not reach significance due to the large standard error. It is possible that the increase in energy expenditure might have been present before day 7. The precise mechanism(s) by which SR141716 increases energy expenditure is not known. However, in vivo microdialysis studies show that SR141716 dose-dependently increases noradrenaline outflow in rat anterior hypothalamus, 23 suggesting a possible central stimulation of efferent sympathetic activity. The organs/ tissues responsible for the increased thermogenesis and whether the uncoupling proteins are upregulated by SR141716 treatment remain to be investigated. Interestingly, a recent report shows SR141716 has a peripheral metabolic action; daily treatment of obese Zucker rats with SR141716 (10 mg/kg) increased Acrp30 expression in adipose tissue.
11
Acrp30 is a secreted protein from adipose tissue and has been shown to induce free fatty acid oxidation and decrease body weight in mice. 24 The Lep ob /Lep ob mice exhibit hyperglycaemia, hyperinsulinemia and insulin resistance. As skeletal muscle plays a predominant role in glucose homeostasis, we then investigated whether SR141716 could affect glucose uptake in isolated soleus muscle of those animals. Treatment with SR141716 for 7 days caused significant increase in soleus muscle glucose uptake. The experiment was undertaken with a very low insulin concentration (10 nM) sufficient only to maintain metabolic function. At this low insulin concentration, the measured rate of 2-deoxyglucose-6-phosphate formation is considered representative of glucose uptake predominantly via the GLUT-1 glucose transporter isoform. The increase of glucose uptake in skeletal muscle could contribute to the improved hyperglycaemia seen with SR141716 treatment in previous studies. 12 The finding that SR141716 stimulates Acrp30 expression 11 suggests that decrease in free fatty acid may be responsible for the increase in glucose uptake due to glucose-fatty acid cycle. Whether SR141716 can directly alter insulin sensitivity and/or responsiveness is under investigation. In summary, results from this study demonstrated for the first time that the cannabinoid receptor antagonist SR141716 activates thermogenesis, suggesting that its antiobesity property is due to the increase in energy expenditure in addition to the initial decrease in food intake. The increase in soleus muscle glucose uptake may contribute to the improved hyperglycaemia seen in the previous studies and indicates its potential role in obesity and NIDDM.
